Abstract
Drug discovery is a complex and costly endeavor, requiring multidisciplinary know-how, interdisciplinary collaboration, tenacity, and a bit of luck. For these reasons, the search for new chemical agents to treat human disease has traditionally been undertaken only within the walls of industry. While the pharmaceutical industry is often successful where it focuses its attention, it generally focuses only on those areas that are allowed by corporate financial realities. Sadly, this means that diseases effecting small populations of patients may go untreated. As a society we should not be content with this situation and must make a priority of the development of new models that will allow and encourage drug discovery in disease areas that are neglected by pharma. In this presentation, I will describe one such model that has been established to find treatments for neurodegenerative diseases.
Keywords: Harvard Center for Neurodegeneration and Repair, Drug Discovery, Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration, pharmaceutical company
Current Alzheimer Research
Title: A New Model for Academics Based Drug Discovery
Volume: 4 Issue: 5
Author(s): Ross L. Stein
Affiliation:
Keywords: Harvard Center for Neurodegeneration and Repair, Drug Discovery, Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration, pharmaceutical company
Abstract: Drug discovery is a complex and costly endeavor, requiring multidisciplinary know-how, interdisciplinary collaboration, tenacity, and a bit of luck. For these reasons, the search for new chemical agents to treat human disease has traditionally been undertaken only within the walls of industry. While the pharmaceutical industry is often successful where it focuses its attention, it generally focuses only on those areas that are allowed by corporate financial realities. Sadly, this means that diseases effecting small populations of patients may go untreated. As a society we should not be content with this situation and must make a priority of the development of new models that will allow and encourage drug discovery in disease areas that are neglected by pharma. In this presentation, I will describe one such model that has been established to find treatments for neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Stein L. Ross, A New Model for Academics Based Drug Discovery, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018280
DOI https://dx.doi.org/10.2174/156720507783018280 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Nanoemulsions for Intranasal Delivery of Riluzole to Improve Brain Bioavailability: Formulation Development and Pharmacokinetic Studies
Current Drug Delivery Pharmaceutical Strategies for Activating Sirtuins
Current Pharmaceutical Design Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Protein Chemistry of Amyloid Fibrils and Chaperones: Implications for Amyloid Formation and Disease
Current Chemical Biology AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease
Current Pharmaceutical Design Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Topiramate: Its Pharmacological Properties and Therapeutic Efficacy in Epilepsy
Mini-Reviews in Medicinal Chemistry Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Pathophysiology of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry